IP Library Granted Patent US 7,879,888
Granted Patent B2
US 7,879,888 · App. 11/915,521 · Granted Feb 1, 2011

Thiazole derivatives and use thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,879,888
App. No.
11/915,521
Granted
Feb 1, 2011
Kind
B2
Abstract

The present invention is related to thiazole derivatives of Formula (I) in particular for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries.

Claims (68)

1. A thiazole derivative according to Formula (I),

wherein:

R 1 is selected from H, acyl, or a substituted acyl;

R 2 is a C 1 -C 6 -alkyl, or substituted C 1 -C 6 -alkyl;

R 3 is selected from the following thienyl groups, defined as T1 and T2:

wherein:

R 4 is selected from:

a sulfonyl group SO 2 —R, wherein R is selected from heteroaryl or heterocycloalkyl; and

R 5 and R 6 are independently selected from H, C 1 -C 6 -alkyl, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl groups; a substituted C 1 -C 6 -alkyl, substituted C 2 -C 6 -alkenyl, substituted C 2 -C 6 -alkynyl groups or halogen;

and isomers, enantiomers, diastereomers, racemates or pharmaceutically acceptable salts thereof.

2. The thiazole derivative according to claim 1 , wherein R 1 is acetyl.

3. The thiazole derivative according to claim 1 , wherein R 2 is methyl.

4. The thiazole derivative according to claim 1 , wherein R 3 is the thienyl group T1.

5. The thiazole derivative according to claim 1 , wherein R 3 is the thienyl group T2.

6. The thiazole derivative according to claim 1 , wherein R 4 is a SO 2 —R and R is heteroaryl.

7. The thiazole derivative according to claim 1 , wherein R 4 is SO 2 —R and R is heterocycloalkyl.

8. The thiazole derivative according to claim 1 , wherein R 5 and R 6 are H.

9. The thiazole derivative according to claim 1 , said thiazole compound being selected from the following compounds:

N-(4-methyl-5-{5-[(prop-2-yn-1-ylamino)sulfonyl]-2-thienyl}-1,3-thiazol-2-yl)acetamide;

N-(5-{5-[(4-acetylpiperazin-1-yl)sulfonyl]-2-thienyl}-4-methyl-1,3-thiazol-2-yl)acetamide;

N-{5-[5-([2-(dimethylamino)ethyl]amino}sulfonyl)-2-thienyl]-4-methyl-1,3-thiazol-2-yl}acetamide;

N-[4-methyl-5-(5-{[(1-methylpiperidin-4-yl)amino]sulfonyl}-2-thienyl)-1,3-thiazol-2-yl]acetamide;

N-[5-(5-{[[2-(dimethylamino)ethyl](methyl)amino]sulfonyl}-2-thienyl)-4-methyl-1,3-thiazol-2-yl]acetamide;

5-(2-amino-4-methyl-1,3-thiazol-5-yl)-N-(2-morpholin-4-ylethyl)thiophene-2-sulfonamide;

methyl5-[4-methyl-5-(5-[(2-morpholin-4-ylethyl)amino]sulfonyl}-2-thienyl)-1,3-thiazol-2-yl]amino}-5-oxopentanoate;

N-(4-methyl-5-{5-[(4-methylpiperazin-1-yl)sulfonyl]-2-thienyl}-1,3-thiazol-2-yl)acetamide;

N-[4-methyl-5-(5-{[(2-morpholin-4-ylethyl)amino]sulfonyl}-2-thienyl)-1,3-thiazol-2-yl]acetamide;

N-{5-[5-({[3-(dimethylamino)propyl]amino}sulfonyl)-2-thienyl]-4-methyl-1,3-thiazol-2-yl}acetamide;

N-{4-methyl-5-[5-(piperazin-1-ylsulfonyl)-2-thienyl]-1,3-thiazol-2-yl}acetamide;

N2-({5-[2-(acetylamino)-4-methyl-1,3-thiazol-5-yl]-2-thienyl}sulfonyl)-N˜1˜-methylglycinamide;

N-{5-[5-({[2-(acetylamino)ethyl]amino}sulfonyl)-2-thienyl}-4-methyl-1,3-thiazol-2-yl]acetamide;

N-{5-[5-({[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]amino}sulfonyl)-2-thienyl]-4-methyl-1,3-thiazol-2-yl}acetamide;

methylN-({5-[2-(acetylamino)-4-methyl-1,3-thiazol-5-yl]-2-thienyl}sulfonyl)serinate;

N-({5-[2-(acetylamino)-4-methyl-1,3-thiazol-5-yl]-2-thienyl}sulfonyl)serine;

N-[5-(5-{[(2,3-dihydroxypropyl)amino]sulfonyl}-2-thienyl)-4-methyl-1,3-thiazol-2-yl]acetamide;

N-(5-{5-[(dimethylamino)sulfonyl]-2-thienyl}-4-methyl-1,3-thiazol-2-yl)acetamide;

N-{4-methyl-5-[5-({-methyl[2-(methylamino)ethyl]amino}sulfonyl)-2-thienyl}-1,3-thiazol-2-yl]acetamide;

N-[5-(5-{[[2-(diethylamino)ethyl](methyl)amino]sulfonyl}-2-thienyl)-4-methyl-1,3-thiazol-2-yl]acetamide;

N-[5-(5-{[(2-methoxyethyl)(methyl)amino]sulfonyl}-2-thienyl)-4-methyl-1,3-thiazol-2-yl]acetamide;

N-[5-(5-{[[2-(dimethylamino)ethyl](ethyl)amino]sulfonyl}-2-thienyl)-4-methyl-1,3-thiazol-2-yl]acetamide;

N-{5-[5-({[2-(dimethylamino)ethyl]amino}sulfonyl)-3-thienyl]-4-methyl-1,3-thiazol}-2-yl}acetamide;

N-[4-methyl-5-(5-{[(2-morpholin-4-ylethyl)amino]sulfonyl}-3-thienyl)-1,3-thiazol-2-yl]acetamide;

N-[4-methyl-5-(5-{[(2-piperidin-1-ylethyl)amino]sulfonyl}-3-thienyl)-1,3-thiazol-2-yl]acetamide;

N-{4-methyl-5-[5-(piperazin-1-ylsulfonyl)-3-thienyl]-1,3-thiazol-2-yl}acetamide;

N-{5-[5-({[3-(dimethylamino)propyl]amino 1 sulfonyl)-3-thienyl]-4-methyl-1,3-thiazol-2-yl}acetamide;

N-[4-methyl-5-(5-{[(1-methylpiperidin-4-yl)amino]sulfonyl}-3-thienyl)-1,3-thiazol-2-yl]acetamide;

N-(4-methyl-5-{5-[(4-methylpiperazin-1-yl)sulfonyl]-3-thienyl}-1,3-thiazol-2-yl)acetamide;

tert-butyl[1-({4-[2-(acetylamino)-4-methyl-1,3-thiazol-5-yl]-2 thienyl}sulfonyl)piperidin-4-yl]methylcarbamate;

N-(5-{5-[(3-hydroxypyrrolidin-1-yl)sulfonyl]-3-thienyl}-4-methyl-1,3-thiazol-2-yl)acetamide;

N-[5-(5-{[(3-hydroxypropyl)amino]sulfonyl}-3-thienyl)-4-methyl-1,3-thiazol-2-yl]acetamide;

N-[5-(5-{[(cis-4-hydroxycyclohexyl)amino]sulfonyl}-3-thienyl)-4-methyl-1,3-thiazol-2-yl]acetamide;

N-(5-{5-[(4-methoxypiperidin-1-yl)sulfonyl]-3-thienyl}-4-methyl-1,3-thiazol-2-yl)acetamide;

N-[4-methyl-5-(5-{[4-(methylamino)piperidin-1-yl]sulfonyl}-3-thienyl)-1,3-thiazol-2-yl]acetamide;

N-[5-(5-{[[2-(dimethylamino)ethyl](methyl)amino]sulfonyl}-3-thienyl)-4-methyl-1,3-thiazol-2-yl]acetamide;

N-[5-(5-{[(1S,5S,7S)-7-(hydroxymethyl)-6,8-dioxa-3-azabicyclo[3.2.1]oct-3-yl]sulfonyl}-3-thienyl)-4-methyl-1,3-thiazol-2-yl]acetamide;

N-[5-(5-{[(2-hydroxyethyl)amino]sulfonyl}-3-thienyl)-4-methyl-1,3-thiazol-2-yl]acetamide;

N-(5-{5-[(4-hydroxypiperidin-1-yl)sulfonyl]-3-thienyl}-4-methyl-1,3-thiazol-2-yl)acetamide;

N-[5-(5-{[(2,3-dihydroxypropyl)amino]sulfonyl}-3-thienyl)-4-methyl-1,3-thiazol-2-yl]acetamide;

N-(4-methyl-5-{5-[(1H-tetrazol-5-ylamino)sulfonyl]-3-thienyl}-1,3-thiazol-2-yl)acetamide;

N-{4-methyl-5-[5-(pyrrolidin-1-ylsulfonyl)-3-thienyl]-1,3-thiazol-2-yl}acetamide;

4-methyl-5-{5-[(4-methylpiperazin-1-yl)sulfonyl]-3-thienyl}-1,3-thiazol-2-amine;

methyl 5-[(4-methyl-5-{5-[(4-methylpiperazin-1-yl)sulfonyl]-3-thienyl]-1,3-thiazol-2-yl)amino}-5-oxopentanoate;

1-{[4-(2-amino-4-methyl-1,3-thiazol-5-yl)-2-thienyl]sulfonyl}piperidin-4-ol;

N-4-methyl-5-[5-methyl-(morpholin-4-ylsulfonyl)-3-thienyl]-1,3-thiazol-2-yl)acetamide;

N-(5-{2-chloro-5-[(4-methylpiperazin-1-yl)sulfonyl]-3-thienyl}-4-methyl-1,3-thiazol-2-yl)acetamide;

N-(5-{5-[(3-hydroxypiperidin-1-yl)sulfonyl]-3-thienyl}-4-methyl-1,3-thiazol-2-yl)acetamide;

N-(5-{5-[(allylamino)sulfonyl]-3-thienyl}-4-methyl-1,3-thiazol-2-yl)acetamide.

10. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier, diluent or excipient thereof.

Assignments (2)
CHANGE OF NAME Recorded Dec 3, 2009
From: LABORATOIRES SERONO SA
To: MERCK SERONO SA
Reel/Frame 023601/0156 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 4, 2008
From: QUATTROPANI, ANNA; COVINI, DAVID; POMEL, VINCENT; DORBAIS, JEROME; RUECKLE, THOMAS
To: LABORATOIRES SERONO SA
Reel/Frame 020316/0432 →